KEVZARA

Phase 2

Regeneron

KEVZARA is one of 47 therapeutic programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[1]

Indication

Rheumatoid ArthritisUnknown

Giant Cell ArteritisActive, not recruiting

Rheumatoid ArthritisPreclinical

Unknown

Giant Cell ArteritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Simponi

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Kineret

SSwedish Orphan Biovitrum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Sources

References

[1]
Open Targets Platform — Drug–disease associations for KEVZARA. EMBL-EBI & Wellcome Sanger Institute.
[2]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2
Company: Regeneron

KEVZARA

Status by Indication[1]

Competitive Landscape

References

Drug Info

Quick Facts

Related News